High materiality9/10
Adma Biologics resumed with an Outperform at Raymond James
Why it may matterVerify against the original reporting
very_bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Raymond James resumes ADMA Biologics with Outperform; target $21; posted price $8.12.
- Raymond James resumes ADMA Biologics with Outperform; target $21; price $8.12.
Key facts
- 01
Target: $21
- 02
Posted price: $8.12
- 03
Analyst firm: Raymond James
- 04
Analyst: Ryan Deschner
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.